ArticlePathophysiology : the official journal of the International Society for Pathophysiology2013
Erythropoietin neuroprotection with traumatic brain injury.
Article in Pathophysiology : the official journal of the International Society for Pathophysiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- An updated systematic review of neuroprotective agents in the treatment of spinal cord injury.Neurosurgical review · 2024Pooled it
- Systematic Review of Erythropoietin (EPO) for Neuroprotection in Human Studies.Neurochemical research · 2021Pooled it
- Potential Efficacy of Erythropoietin on Reducing the Risk of Mortality in Patients with Traumatic Brain Injury: A Systematic Review and Meta-Analysis.BioMed research international · 2020Pooled it
- Insights into the Effects of Carbamylated Erythropoietin on Schwann Cells in Peripheral Nerve Injury.International journal of molecular sciences · 2026Article
- Synaptic aging and neurodegeneration: the role of synaptic vesicle dynamics and neurotransmitter imbalance.Biogerontology · 2026Review
- Revealing erythropoietin variant EV-3 as novel driving force and immunotherapeutic target in human glioblastoma.Journal of experimental & clinical cancer research : CR · 2025Article
- Traumatic Brain Injury: Advances in Diagnostic Techniques and Treatment Modalities.Journal of clinical medicine · 2025Review
- Clinical Management in Traumatic Brain Injury.Biomedicines · 2024Review
- Neuroprotection strategies in traumatic brain injury: Studying the effectiveness of different clinical approaches.Surgical neurology international · 2024Review
- Cardiomyocyte crosstalk with endothelium modulates cardiac structure, function, and ischemia-reperfusion injury susceptibility through erythropoietin.Frontiers in physiology · 2024Article
- Unravelling the potential neuroprotective facets of erythropoietin for the treatment of Alzheimer's disease.Metabolic brain disease · 2022Review
- Venlafaxine Mitigates Depressive-Like Behavior in Ovariectomized Rats by Activating the EPO/EPOR/JAK2 Signaling Pathway and Increasing the Serum Estradiol Level.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2019Article
- Effects of erythropoietin on bile duct ligation-induced neuro-inflammation in male rats.AIMS neuroscience · 2019Article
- Neuroprotective effect of a new variant of Epo nonhematopoietic against oxidative stress.Redox biology · 2018Article
- Erythropoietin Rescues Memory Impairment in a Rat Model of Chronic Cerebral Hypoperfusion via the EPO-R/JAK2/STAT5/PI3K/Akt/GSK-3β Pathway.Molecular neurobiology · 2018Article
- Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor.Neural regeneration research · 2017Review
- Traumatic Brain Injury: Current Treatment Strategies and Future Endeavors.Cell transplantation · 2017Review
- Brain adaptation to hypoxia and hyperoxia in mice.Redox biology · 2017Article
- Imaging and serum biomarkers reflecting the functional efficacy of extended erythropoietin treatment in rats following infantile traumatic brain injury.Journal of neurosurgery. Pediatrics · 2016Article
- Charting a course for erythropoietin in traumatic brain injury.Journal of translational science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Numerous experimental studies in recent years have suggested that erythropoietin (EPO) is an endogenous mediator of neuroprotection in various central nervous system disorders, including TBI. Many characteristics of EPO neuroprotection that have been defined in TBI experimental models suggest that it is an attractive candidate for a new treatment of TBI. EPO targets multiple mechanisms known to cause secondary injury after TBI, including anti-excitotoxic, antioxidant, anti-edematous, and anti-inflammatory mechanisms. EPO crosses the blood-brain barrier. EPO has a known dose response and time window for neuroprotection and neurorestoration that would be practical in the clinical setting. However, EPO also stimulates erythropoiesis, which can result in thromboembolic complications. Derivatives of EPO which do not bind to the classical EPO receptor (carbamylated EPO) or that have such a brief half-life in the circulation that they do not stimulate erythropoiesis (asialo EPO and neuro EPO) have the neuroprotective activities of EPO without these potential thromboembolic adverse effects associated with EPO administration. Likewise, a peptide based on the structure of the Helix B segment of the EPO molecule that does not bind to the EPO receptor (pyroglutamate Helix B surface peptide) has promise as another alternative to EPO that may provide neuroprotection without stimulating erythropoiesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.